Targeting liver X receptors in inflammation
The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: The two oxysterol receptors, 'liver X receptors (LXRs)' LXRα and LXRβ, are amongst the emerging newer drug targets within the nuclear receptor family and targeting LXRs represents novel strategies needed for prevention and treatment of diseases where current therapeutics is inadequate. AREAS COVERED: This review discusses the current understanding of LXR biology with an emphasis on the molecular aspects of LXR signalling establishing their potential as drug targets. Recent advances of their transcriptional mechanisms in inflammatory pathways and their physiological roles in inflammation and immunity are described. EXPERT OPINION: The new discoveries of LXR-regulated inflammatory pathways have ignited new promises for LXRs as drug targets. The broad physiological roles of LXRs involve a high risk of unwanted side effects. Recent insights into LXR biology of the brain indicate a highly important role in neuronal development and a clinical trial testing an LXR agonist reported adverse neurological side effects. This suggests that drug development must focus on limiting the range of LXR signalling - possibly achieved through subtype, tissue specific, promoter specific or pathway specific activation of LXRs where a successful candidate drug must be carefully studied for its effect in the central nervous system.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ballard, C., Gauthier, S., Corbett, A., Brayne, C., Aarsland, D., & Jones, E. (2011) · The Lancet · doi:10.1016/s0140-6736(10)61349-9 · Cited by 2,336
Activation of the Nuclear Receptor LXR by Oxysterols Defines a New Hormone Response Pathway
Lehmann, J. M., Kliewer, S. A., Moore, L. B., Smith-Oliver, T. A., Oliver, B. B., Su, J.-L., Sundseth, S. S., Winegar, D. A., Blanchard, D. E., Spencer, T. A., et al. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.6.3137 · Cited by 1,233 · cited 1×
“These oxidised cholesterol metabolites include 24(S)-hydroxycholesterol, 22(R)-hydroxycholesterol, 24(S), 25-epoxycholesterol and 27-hydroxycholesterol [3,4].”
BackgroundReciprocal regulation of inflammation and lipid metabolism by liver X receptors
Joseph, S. B., Castrillo, A., Laffitte, B. A., Mangelsdorf, D. J., & Tontonoz, P. (2003) · Nature Medicine · doi:10.1038/nm820 · Cited by 1,158
Liver X receptors as integrators of metabolic and inflammatory signaling
Zelcer, N. (2006) · Journal of Clinical Investigation · doi:10.1172/jci27883 · Cited by 978 · cited 1×
“Human LXRa (447 amino acids) and LXRb (460 amino acids) share 77% sequence homology in the DBDs and LBDs [14] and the crystal structure of LXRs revealed a very flexible LBP allowing compounds of highly different structure to bind [15,16].”
BackgroundRobust expansion of human hepatocytes in Fah−/−/Rag2−/−/Il2rg−/− mice
Azuma, H., Paulk, N., Ranade, A., Dorrell, C., Al-Dhalimy, M., Ellis, E., Strom, S., Kay, M. A., Finegold, M., & Grompe, M. (2007) · Nature Biotechnology · doi:10.1038/nbt1326 · Cited by 835
Understanding the dynamics: pathways involved in the pathogenesis of rheumatoid arthritis.
Choy, E. (2012) · Rheumatology · doi:10.1093/rheumatology/kes113 · Cited by 816
Transcriptional integration of metabolism by the nuclear sterol-activated receptors LXR and FXR
Calkin, A. C., & Tontonoz, P. (2012) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3312 · Cited by 779 · cited 1×
“Many roles of the LXRs controlling metabolic homeostasis and proliferation will not be considered in detail here, but readers are referred to the following reviews for a broader understanding of the biology of LXRs [32-35].”
BackgroundMolecular determinants of crosstalk between nuclear receptors and toll-like receptors
Ogawa, S., Lozach, J., Benner, C., Pascual, G., Tangirala, R. K., Westin, S., Hoffmann, A., Subramaniam, S., David, M., Rosenfeld, M. G., et al. (2005) · Cell · doi:10.1016/j.cell.2005.06.029 · Cited by 647
Ghisletti, S., Huang, W., Ogawa, S., Pascual, G., Lin, M.-E., Willson, T. M., Rosenfeld, M. G., & Glass, C. K. (2007) · Molecular Cell · doi:10.1016/j.molcel.2006.11.022 · Cited by 561 · cited 9×
“A variety of PTMs have been reported to affect the transcriptional activity of LXRs including ubiquitination [22,23], phosphorylation [24-26], O-GlcNAcylation [27] and SUMOylation [28].”
BackgroundInfluentialYvan-Charvet, L., Ranalletta, M., Wang, N., Han, S., Terasaka, N., Li, R., Welch, C., & Tall, A. R. (2007) · Journal of Clinical Investigation · doi:10.1172/jci33372 · Cited by 536
Cited by
Oxidized cholesterol as the driving force behind the development of Alzheimer’s disease
Gamba, P., Testa, G., Gargiulo, S., Staurenghi, E., Poli, G., & Leonarduzzi, G. (2015) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2015.00119 · Cited by 180
The challenges and promise of targeting the Liver X Receptors for treatment of inflammatory disease
Fessler, M. B. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.07.010 · Cited by 173
Ma, Z., Deng, C., Hu, W., Zhou, J., Fan, C., Di, S., Liu, D., Yang, Y., & Wang, D. (2017) · Current Issues in Molecular Biology · doi:10.21775/cimb.022.041 · Cited by 70
Metadata
- Authors
- Steffensen, K. R., Jakobsson, T., & Gustafsson, J.-Å.
- Venue
- Expert Opinion on Therapeutic Targets
- Publisher
- Informa UK Limited
- Published
- 2013-06-06
- Volume
- 17
- Issue
- 8
- Pages
- 977-990
- ISSN
- 1472-8222 (ISSN-L)
- 1744-7631
- OpenAlex
- W2022742910
- Cited by
- 63
- References
- 20
- FWCI
- 8.08
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Targeting liver X receptors in inflammation. https://app.cochat.ai/papers/10.1517/14728222.2013.806490
- The paper
- Steffensen, K. R., Jakobsson, T., & Gustafsson, J.-Å. (2013). Targeting liver X receptors in inflammation. Expert Opinion on Therapeutic Targets. https://doi.org/10.1517/14728222.2013.806490
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.